Treatment of Hepatitis C in Psychiatric Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

81 participants

Study Classification

OBSERVATIONAL

Study Start Date

1999-08-31

Study Completion Date

2002-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psychiatric disorders or drug addiction are often regarded as contraindications against the use of Interferon-alpha in patients with chronic hepatitis C. The investigators aim is/was to get prospective data about adherence, efficacy and mental side effects of IFN-alpha treatment in different psychiatric risk groups compared to controls. In a prospective trial, 81 patients with chronic hepatitis C (positive HCV-RNA and elevated ALT) and psychiatric disorders (n=16), methadone substitution (n=21), former drug addiction (n=21) or controls without psychiatric history or addiction (n=23) should be/were treated with a combination of IFN-alpha-2a 3 x 3 Mio U/week and ribavirin (1000-1200 mg/day).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Overcoming Psychiatric Barriers to the Treatment of Hepatitis C

NCT00407732

Hepatitis C Substance Use Disorders Mental Disorder

COMPLETED NA

Hepatitis C Translating Initiatives for Depression Into Effective Solutions

NCT01143896

Hepatitis C Depression

COMPLETED NA

Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1

NCT00218556

Depressive Disorder, Major Hepatitis C

COMPLETED NA

HCV Treatment Initiation During Acute Psychiatric Admission

NCT04625322

Hepatitis C

UNKNOWN PHASE4

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

NCT00655226

Hepatitis C Depressive Disorder, Major Depressive Disorder +2 more

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients from the Munich University outpatient department of psychiatry or gastroenterology as well as inpatients with elevated transaminases were tested for HCV-infection and considered for our trial to avoid a positive or negative selection. Medical inclusion criteria were a detectable serum HCV-RNA level in a PCR-based assay (AMPLICOR®, Roche Diagnostics, Branchburg, NJ) for more than 6 months and an elevated alanine aminotransferase (ALT \> 30 U/L, normal \<24 U/L). General exclusion criteria were the presence of other liver disease, Child B or C cirrhosis, severe cardiac or neurological disease, co-infection with hepatitis B or HIV, hepatocellular carcinoma evaluated by ultrasound and alpha-fetoprotein, autoimmune disorders, a neutrophil count below 1500 per cubic millimetre, and a platelet count below 75000 per cubic millimetre.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mental Disorders Drug Addiction

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* Child B or C cirrhosis
* Severe cardiac or neurological disease
* Co-infection with hepatitis B or HIV
* Hepatocellular carcinoma evaluated by ultrasound and alpha-fetoprotein
* Autoimmune disorders
* Neutrophil count below 1500 per cubic millimetre
* Platelet count below 75000 per cubic millimetre

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No